摘要
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)作为肿瘤免疫治疗的革命性药物,在发挥抗肿瘤作用的同时,也会攻击自身正常组织,引起一系列不良反应,称为免疫相关不良反应(immune-related adverse event,IrAEs)。大部分IrAEs较轻微,少数严重IrAEs会使肿瘤免疫治疗复杂化,甚至停止免疫治疗影响病人治疗效果,因此,需要更好地了解IrAEs的发病机制,为及早发现、及时处理IrAEs提供扎实的理论基础。该研究旨在全面阐述IrAEs的发病机制相关知识,为其临床应用和未来研究提供参考。
Immune checkpoint inhibitors(ICIs),as a revolutionary drug for tumor immunotherapy,may attack normal tissues while exerting their anti-tumor effects,causing a series of immune-related adverse events(IrAEs).Most of the IrAEs are mild,and a small number of severe IrAEs can complicate the tumor immunotherapy,and even stop the immunotherapy,affecting the treatment effect of patients.Therefore,it is necessary to better understand the pathogenesis of IrAEs,so as to provide a solid theoretical basis for early detection and timely treatment of IrAEs.The purpose of this article is to comprehensively elaborate the relevant knowledge of IrAEs pathogenesis,providing reference for its clinical application and future research.
作者
闫珍影
贺建霞
YAN Zhenying;HE Jianxia(Hematology Department,Shanxi Provincial People's Hospital Affiliated with Shanxi Medical University,Taiyuan,Shanxi 030012,China)
出处
《安徽医药》
2025年第10期1914-1918,共5页
Anhui Medical and Pharmaceutical Journal
基金
山西省自然科学基金项目(201901D111435)。
